Journal of Cancer Survivorship

, Volume 4, Issue 2, pp 101–109

Alcohol consumption and non-Hodgkin lymphoma survival

  • Xuesong Han
  • Tongzhang Zheng
  • Francine M. Foss
  • Shuangge Ma
  • Theodore R. Holford
  • Peter Boyle
  • Brian Leaderer
  • Ping Zhao
  • Min Dai
  • Yawei Zhang
Article

Abstract

Introduction

Epidemiological studies have shown that moderate alcohol drinkers have a lower death rate for all causes. Alcohol drinking has also been associated with reduced risk of non-Hodgkin lymphoma (NHL). Here, we examined the role of alcohol consumption on NHL survival by type of alcohol consumed and NHL subtype.

Methods

A cohort of 575 female NHL incident cases diagnosed during 1996–2000 in Connecticut was followed-up for a median of 7.75 years. Demographic, clinical, and lifestyle information was collected at diagnosis. Survival analyses were conducted with Kaplan-Meier methods, and hazard ratios (HR) were estimated from Cox Proportional Hazards models.

Results

Compared to never drinkers, wine drinkers experienced better overall survival (75% vs. 69% five-year survival rates, p-value for log-rank test = 0.030) and better disease free survival (70% vs. 67% five-year disease-free survival rates, p-value for log-rank test = 0.049). Analysis by NHL subtype shows that the favorable effect of wine consumption was mainly seen for patients diagnosed with diffuse large B-cell lymphoma (DLBCL) (wine drinkers for more than 25 years vs. never drinkers: HR = 0.36, 95% CI 0.14–0.94 for overall survival; HR = 0.38, 95% CI 0.16–0.94 for disease-free survival), and the adverse effect of liquor consumption was also observed among DLBCL patients (liquor drinkers vs. never drinkers: HR=2.49, 95% CI 1.26–4.93 for disease-free survival).

Conclusions

Our results suggest a moderate relationship between pre-diagnostic alcohol consumption and NHL survival, particularly for DLBCL. The results need to be replicated in larger studies.

Implications for cancer survivors

Pre-diagnostic behaviors might impact the prognosis and survival of NHL patients.

Keywords

Alcohol Wine Liquor Non-Hodgkin lymphoma Prognosis Survival 

References

  1. 1.
    Kloner RA, Rezkalla SH. To drink or not to drink? That is the question. Circulation. 2007;116:1306–17.CrossRefPubMedGoogle Scholar
  2. 2.
    Ginter E, Simko V. Ethanol and cardiovascular diseases: epidemiological, biochemical and clinical aspects. Bratisl Lek Listy. 2008;109:590–4.PubMedGoogle Scholar
  3. 3.
    Djousse L, Gaziano JM. Alcohol consumption and heart failure: a systematic review. Curr Atheroscler Rep. 2008;10:117–20.CrossRefPubMedGoogle Scholar
  4. 4.
    McCullough MJ, Farah CS. The role of alcohol in oral carcinogenesis with particular reference to alcohol-containing mouthwashes. Aust Dent J. 2008;53:302–5.CrossRefPubMedGoogle Scholar
  5. 5.
    Holmes RS, Vaughan TL. Epidemiology and pathogenesis of esophageal cancer. Semin Radiat Oncol. 2007;17:2–9.CrossRefPubMedGoogle Scholar
  6. 6.
    Marrero JA. Hepatocellular carcinoma. Curr Opin Gastroenterol. 2006;22:248–53.CrossRefPubMedGoogle Scholar
  7. 7.
    Secretan B, Straif K, Baan R, Grosse Y, El Ghissassi F, Bouvard V, et al. A review of human carcinogens–Part E: tobacco, areca nut, alcohol, coal smoke, and salted fish. Lancet Oncol. 2009;10:1033–4.CrossRefPubMedGoogle Scholar
  8. 8.
    Morton LM, Zheng T, Holford TR, Holly EA, Chiu BC, Costantini AS, et al. Alcohol consumption and risk of non-Hodgkin lymphoma: a pooled analysis. Lancet Oncol. 2005;6:469–76.CrossRefPubMedGoogle Scholar
  9. 9.
    Allen NE, Beral V, Casabonne D, Kan SW, Reeves GK, Brown A, et al. Moderate alcohol intake and cancer incidence in women. J Natl Cancer Inst. 2009;101:296–305.CrossRefPubMedGoogle Scholar
  10. 10.
    Chiu BC, Cerhan JR, Gapstur SM, Sellers TA, Zheng W, Lutz CT, et al. Alcohol consumption and non-Hodgkin lymphoma in a cohort of older women. Br J Cancer. 1999;80:1476–82.CrossRefPubMedGoogle Scholar
  11. 11.
    Klatsky AL, Li Y, Baer D, Armstrong MA, Udaltsova N, Friedman GD. Alcohol consumption and risk of hematologic malignancies. Ann Epidemiol 2009.Google Scholar
  12. 12.
    Lim U, Morton LM, Subar AF, Baris D, Stolzenberg-Solomon R, Leitzmann M, et al. Alcohol, smoking, and body size in relation to incident Hodgkin’s and non-Hodgkin’s lymphoma risk. Am J Epidemiol. 2007;166:697–708.CrossRefPubMedGoogle Scholar
  13. 13.
    Diaz LE, Montero A, Gonzalez-Gross M, Vallejo AI, Romeo J, Marcos A. Influence of alcohol consumption on immunological status: a review. Eur J Clin Nutr. 2002;56 Suppl 3:S50–3.CrossRefPubMedGoogle Scholar
  14. 14.
    Poschl G, Seitz HK. Alcohol and cancer. Alcohol and alcoholism. 2004;39:155–65.PubMedGoogle Scholar
  15. 15.
    Battaglioli T, Gorini G, Costantini AS, Crosignani P, Miligi L, Nanni O, et al. Cigarette smoking and alcohol consumption as determinants of survival in non-Hodgkin’s lymphoma: a population-based study. Ann Oncol. 2006;17:1283–9.CrossRefPubMedGoogle Scholar
  16. 16.
    Talamini R, Polesel J, Spina M, Chimienti E, Serraino D, Zucchetto A, et al. The impact of tobacco smoking and alcohol drinking on survival of patients with non-Hodgkin lymphoma. Int J Cancer. 2008;122:1624–9.CrossRefPubMedGoogle Scholar
  17. 17.
    Zhang Y, Holford TR, Leaderer B, Boyle P, Zahm SH, Flynn S, et al. Hair-coloring product use and risk of non-Hodgkin’s lymphoma: a population-based case-control study in Connecticut. Am J Epidemiol. 2004;159:148–54.CrossRefPubMedGoogle Scholar
  18. 18.
    Morton LM, Holford TR, Leaderer B, Zhang Y, Zahm SH, Boyle P, et al. Alcohol use and risk of non-Hodgkin’s lymphoma among Connecticut women (United States). Cancer Causes Control. 2003;14:687–94.CrossRefPubMedGoogle Scholar
  19. 19.
    A clinical evaluation of the International Lymphoma Study Group classification of non-Hodgkin’s lymphoma. The Non-Hodgkin’s Lymphoma Classification Project. Blood 1997;89:3909–18.Google Scholar
  20. 20.
    Harris NL, Jaffe ES, Diebold J, Flandrin G, Muller-Hermelink HK, Vardiman J, et al. World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues: report of the Clinical Advisory Committee meeting-Airlie House, Virginia, November 1997. J Clin Oncol. 1999;17:3835–49.PubMedGoogle Scholar
  21. 21.
    Ghali WA, Quan H, Brant R, van Melle G, Norris CM, Faris PD, et al. Comparison of 2 methods for calculating adjusted survival curves from proportional hazards models. Jama. 2001;286:1494–7.CrossRefPubMedGoogle Scholar
  22. 22.
    Nieto FJ, Coresh J. Adjusting survival curves for confounders: a review and a new method. Am J Epidemiol. 1996;143:1059–68.PubMedGoogle Scholar
  23. 23.
    He S, Sun C, Pan Y. Red wine polyphenols for cancer prevention. Int J Mol Sci. 2008;9:842–53.CrossRefPubMedGoogle Scholar
  24. 24.
    Fernandez-Panchon MS, Villano D, Troncoso AM, Garcia-Parrilla MC. Antioxidant activity of phenolic compounds: from in vitro results to in vivo evidence. Crit Rev Food Sci Nutr. 2008;48:649–71.CrossRefPubMedGoogle Scholar
  25. 25.
    Udenigwe CC, Ramprasath VR, Aluko RE, Jones PJ. Potential of resveratrol in anticancer and anti-inflammatory therapy. Nutr Rev. 2008;66:445–54.CrossRefPubMedGoogle Scholar
  26. 26.
    de la Lastra CA, Villegas I. Resveratrol as an anti-inflammatory and anti-aging agent: mechanisms and clinical implications. Mol Nutr Food Res. 2005;49:405–30.CrossRefPubMedGoogle Scholar
  27. 27.
    Delmas D, Lancon A, Colin D, Jannin B, Latruffe N. Resveratrol as a chemopreventive agent: a promising molecule for fighting cancer. Curr Drug Targets. 2006;7:423–42.CrossRefPubMedGoogle Scholar
  28. 28.
    Benitez DA, Pozo-Guisado E, Alvarez-Barrientos A, Fernandez-Salguero PM, Castellon EA. Mechanisms involved in resveratrol-induced apoptosis and cell cycle arrest in prostate cancer-derived cell lines. J Androl. 2007;28:282–93.CrossRefPubMedGoogle Scholar
  29. 29.
    Bishayee A, Dhir N. Resveratrol-mediated chemoprevention of diethylnitrosamine-initiated hepatocarcinogenesis: inhibition of cell proliferation and induction of apoptosis. Chem Biol Interact. 2009;179:131–44.CrossRefPubMedGoogle Scholar
  30. 30.
    Kuo PL, Hsu YL. The grape and wine constituent piceatannol inhibits proliferation of human bladder cancer cells via blocking cell cycle progression and inducing Fas/membrane bound Fas ligand-mediated apoptotic pathway. Mol Nutr Food Res. 2008;52:408–18.CrossRefPubMedGoogle Scholar
  31. 31.
    Leifert WR, Abeywardena MY. Grape seed and red wine polyphenol extracts inhibit cellular cholesterol uptake, cell proliferation, and 5-lipoxygenase activity. Nutr Res. 2008;28:842–50.CrossRefPubMedGoogle Scholar
  32. 32.
    Lee KW, Kang NJ, Heo YS, Rogozin EA, Pugliese A, Hwang MK, et al. Raf and MEK protein kinases are direct molecular targets for the chemopreventive effect of quercetin, a major flavonol in red wine. Cancer Res. 2008;68:946–55.CrossRefPubMedGoogle Scholar
  33. 33.
    Lee KW, Kang NJ, Rogozin EA, Kim HG, Cho YY, Bode AM, et al. Myricetin is a novel natural inhibitor of neoplastic cell transformation and MEK1. Carcinogenesis. 2007;28:1918–27.CrossRefPubMedGoogle Scholar
  34. 34.
    Shimizu T, Nakazato T, Xian MJ, Sagawa M, Ikeda Y, Kizaki M. Resveratrol induces apoptosis of human malignant B cells by activation of caspase-3 and p38 MAP kinase pathways. Biochem Pharmacol. 2006;71:742–50.CrossRefPubMedGoogle Scholar
  35. 35.
    King RE, Kent KD, Bomser JA. Resveratrol reduces oxidation and proliferation of human retinal pigment epithelial cells via extracellular signal-regulated kinase inhibition. Chem Biol Interact. 2005;151:143–9.CrossRefPubMedGoogle Scholar
  36. 36.
    D'Archivio M, Santangelo C, Scazzocchio B, Vari R, Filesi C, Masella R, et al. Modulatory effects of polyphenols on apoptosis induction: relevance for cancer prevention. Int J Mol Sci. 2008;9:213–28.CrossRefPubMedGoogle Scholar
  37. 37.
    Juan ME, Wenzel U, Daniel H, Planas JM. Resveratrol induces apoptosis through ROS-dependent mitochondria pathway in HT-29 human colorectal carcinoma cells. J Agric Food Chem. 2008;56:4813–8.CrossRefPubMedGoogle Scholar
  38. 38.
    Larrosa M, Tomas-Barberan FA, Espin JC. The grape and wine polyphenol piceatannol is a potent inducer of apoptosis in human SK-Mel-28 melanoma cells. Eur J Nutr. 2004;43:275–84.CrossRefPubMedGoogle Scholar
  39. 39.
    Hertog MG, Kromhout D, Aravanis C, Blackburn H, Buzina R, Fidanza F, et al. Flavonoid intake and long-term risk of coronary heart disease and cancer in the seven countries study. Arch Intern Med. 1995;155:381–6.CrossRefPubMedGoogle Scholar
  40. 40.
    Knekt P, Jarvinen R, Reunanen A, Maatela J. Flavonoid intake and coronary mortality in Finland: a cohort study. BMJ. 1996;312:478–81.PubMedGoogle Scholar
  41. 41.
    Hirvonen T, Pietinen P, Virtanen M, Ovaskainen ML, Hakkinen S, Albanes D, et al. Intake of flavonols and flavones and risk of coronary heart disease in male smokers. Epidemiology. 2001;12:62–7.CrossRefPubMedGoogle Scholar
  42. 42.
    Yochum L, Kushi LH, Meyer K, Folsom AR. Dietary flavonoid intake and risk of cardiovascular disease in postmenopausal women. Am J Epidemiol. 1999;149:943–9.PubMedGoogle Scholar
  43. 43.
    Rotondo S, Di Castelnuovo A, de Gaetano G. The relationship between wine consumption and cardiovascular risk: from epidemiological evidence to biological plausibility. Ital Heart J. 2001;2:1–8.PubMedGoogle Scholar
  44. 44.
    Streppel MT, Ocke MC, Boshuizen HC, Kok FJ, Kromhout D. Long-term wine consumption is related to cardiovascular mortality and life expectancy independently of moderate alcohol intake: the Zutphen Study. J Epidemiol Community Health 2009.Google Scholar
  45. 45.
    Athyros VG, Liberopoulos EN, Mikhailidis DP, Papageorgiou AA, Ganotakis ES, Tziomalos K, et al. Association of drinking pattern and alcohol beverage type with the prevalence of metabolic syndrome, diabetes, coronary heart disease, stroke, and peripheral arterial disease in a Mediterranean cohort. Angiology. 2007;58:689–97.CrossRefPubMedGoogle Scholar
  46. 46.
    Demark-Wahnefried W, Rock CL, Patrick K, Byers T. Lifestyle interventions to reduce cancer risk and improve outcomes. Am Fam Physician. 2008;77:1573–8.PubMedGoogle Scholar
  47. 47.
    Surveillance, Epidemiology, and End Results (SEER) Program (www.seer.cancer.gov) SEER*Stat Database: Incidence—SEER 17 Regs Limited-Use + Hurricane Katrina Impacted Louisiana Cases, Nov 2007 Sub (1973–2005 varying)—Linked To County Attributes—Total U.S., 1969–2005 Counties, National Cancer Institute, DCCPS, Surveillance Research Program, Cancer Statistics Branch, released April 2008, based on the November 2007 submission.

Copyright information

© Springer Science+Business Media, LLC 2009

Authors and Affiliations

  • Xuesong Han
    • 1
  • Tongzhang Zheng
    • 1
  • Francine M. Foss
    • 2
  • Shuangge Ma
    • 1
  • Theodore R. Holford
    • 1
  • Peter Boyle
    • 3
  • Brian Leaderer
    • 1
  • Ping Zhao
    • 4
  • Min Dai
    • 4
  • Yawei Zhang
    • 1
    • 5
  1. 1.School of Public HealthYale UniversityNew HavenUSA
  2. 2.School of MedicineYale UniversityNew HavenUSA
  3. 3.International Prevention Research InstituteLyonFrance
  4. 4.Cancer Institute/HospitalChinese Academy of Medical SciencesBeijingPeople’s Republic of China
  5. 5.Yale University School of Public HealthNew HavenUSA

Personalised recommendations